Flavokawain a Ameliorates Pulmonary Fibrosis by Inhibiting the TGF-β Signaling Pathway and CXCL12/CXCR4 Axis

Investigators evaluated the effect of flavokawain A (FKA) on pulmonary fibrosis using an animal model of bleomycin-induced pulmonary fibrosis and showed that FKA alleviated the development of pulmonary fibrosis in a dose-dependent manner and improved lung function as well as collagen deposition and extracellular matrix accumulation in mice.